Neuroleptic malignant syndrome.
Neuroleptic malignant syndrome is a rare but serious adverse effect of antipsychotic medication. The author describes three new cases and reviews 50 others published in the past 5 years. Demographic and clinical features, diagnosis, treatment, outcome, and pathophysiology are critically reviewed, and a new set of diagnostic criteria, incorporating physical signs and routine laboratory tests, is proposed.
Levenson
J L
JL
D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology; D001480:Basal Ganglia Diseases / Q000175:diagnosis*; D001971:Bromocriptine / Q000627:therapeutic use; D002648:Child; D003620:Dantrolene / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004298:Dopamine / Q000502:physiology; D018492:Dopamine Antagonists; D005260:Female; D006801:Humans; D008297:Male; D008305:Malignant Hyperthermia / Q000175:diagnosis; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D011618:Psychotic Disorders / Q000188:drug therapy; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D012206:Rhabdomyolysis / Q000175:diagnosis; D012559:Schizophrenia / Q000188:drug therapy
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D001971:Bromocriptine; D003620:Dantrolene; D004298:Dopamine